New Delhi, India, 31 December 2021 — Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) recently received registration approval from the Indian Central Drugs Standard Control Organization (CDSCO) for its Hercules™ Low Profile Thoracic Stent Graft and Delivery System (Hercules™-LP). This milestone marks the first Endovastec™ product to be approved for marketing in India.
Hercules™-LP builds on the technology of the Hercules™ thoracic stent graft system and is primarily indicated for the intervention of thoracic aortic aneurysms with a proximal/distal aneurysm neck length greater than 15 mm. The product is designed with a tip-capture mechanism, which results in a significant improvement in both accuracy and stability of stent positioning and release.
In comparison to the Hercules™ thoracic stent graft system, it has a considerably smaller delivery sheath, with an outer diameter that has been reduced to 18 F for the first time. In addition, the PET soft inner sheath protects the stent system to easily cross the aortic arch. The multiple taper design of the stent, ranging from 0-10 mm, is able to better conform to the anatomical morphology of thoracic aortic dissection, and the ability of the sloped stent to readily conform to the anatomy of the aorta enhances the overall flexibility.
According to reports, India, the second most populous country in the world, suffers from a high prevalence of hypertension and diabetes, which are the main causes of aortic disease. The approval of Hercules™-LP in India will benefit more local patients with its excellent performance, providing both doctors and patients with a better solution for treating thoracic aortic disease and laying the foundation for the company to further develop overseas markets.
The Hercules™-LP received CE marking in 2020 and is currently available in several overseas countries in South America and Asia.
About Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), a subsidiary of MicroPort Scientific Corporation, was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New “Little Giant” Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.